METABOLIC & WEIGHT RESEARCH / MATRIX
Three Mechanisms, Three Evidence Tiers
How a mitochondrial-derived peptide, an investigational triple agonist, and an approved GLP-1 receptor agonist differ — and why treating their evidence as equivalent would be a mistake.
The short version
This page lines up MOTS-c, retatrutide, and semaglutide on the dimensions that matter most for reading metabolic-peptide research honestly: mechanism, most-studied application, evidence maturity, regulatory standing, and the single caution that matters most for each. The headline finding is not subtle: these three occupy three genuinely different rungs of evidence. Semaglutide is an FDA-approved medicine with a decade-plus trial record. Retatrutide is an investigational drug with two years of promising Phase 2 data and no Phase 3 results yet. MOTS-c is a research-only peptide with essentially no human trial data at all. None of this is medical advice, and no dose is recommended anywhere on this page.
The comparison matrix
| Dimension | MOTS-c | Retatrutide | Semaglutide |
|---|---|---|---|
| Compound class | Mitochondrial-derived peptide (MDP) | GIP/GLP-1/glucagon triple receptor agonist | GLP-1 receptor agonist |
| Proposed mechanism | AMPK activation via folate-cycle inhibition; nuclear retrograde signaling [3][5] | Appetite suppression (GLP-1/GIP) plus glucagon-driven energy expenditure [6][7] | Appetite suppression and glucose-dependent insulin secretion via GLP-1R [16] |
| Most-studied in | Mouse models of muscle metabolism, exercise, and aging; one human observational cohort | Obesity, type 2 diabetes, metabolic liver disease (MASLD) | Type 2 diabetes, obesity, cardiovascular and kidney outcomes |
| Evidence base | Preclinical (mouse/cell) plus one small human association study [1][2][4][5] | Phase 2 RCTs only; Phase 3 ongoing [8][9][10] | Large Phase 3 RCTs across multiple indications [12][13][14][17] |
| Regulatory status | Not approved; sold only as a research chemical | Investigational; not approved anywhere as of mid-2026 | FDA-approved (multiple indications) |
| Key caution | No human efficacy or safety data exist for exogenous use | Unverified sourcing outside trials; unresolved long-term cardiovascular signal [9] | GI intolerance and substantial weight regain after stopping [15][14] |
Mechanism
Semaglutide and retatrutide both work by activating incretin receptors that gut hormones normally engage — semaglutide at one (GLP-1R), retatrutide at three (GLP-1R, GIPR, and the glucagon receptor GCGR), with cryo-EM work showing it engages each of the three differently rather than uniformly [7]. MOTS-c does not touch those receptors at all; it is proposed to act from inside the mitochondrion, inhibiting folate-cycle enzymes to activate AMPK and, under stress, moving to the cell nucleus to help regulate gene expression [3][5]. The three compounds therefore aren't variations on one mechanism — they represent genuinely different metabolic strategies that happen to converge on the same broad research interest: weight and glucose regulation.
Evidence maturity
This is where the three separate most sharply. Semaglutide's evidence spans multiple large randomized trials across different populations and endpoints, plus years of post-marketing safety data [12][13][14][15][17]. Retatrutide's entire evidence base is Phase 2: a handful of trials with several hundred participants each, all published in the last few years, with Phase 3 results not yet reported [8][9][10]. MOTS-c has no completed interventional human trial at all — its evidence is confined to mouse and cell-based experiments plus a single observational cohort study that links naturally occurring MOTS-c levels to cardiovascular risk, which is not the same as testing MOTS-c as a treatment [1][2][4][5]. Treating a Phase 2 signal and a mouse study as comparable to a decade of Phase 3 trials would misrepresent all three.
Regulatory and availability status
Semaglutide is an FDA-approved prescription medicine across several indications. Retatrutide is not approved by any regulator as of mid-2026; it is available only within registered clinical trials, and material sold outside that context carries no verified identity or purity [6][9]. MOTS-c has no regulatory approval pathway underway and is sold exclusively as a laboratory research chemical, not intended for human use; anti-doping authorities separately prohibit its use in competitive sport. None of the three is available, or should be understood, as an over-the-counter or self-directed product.
Key caution
For semaglutide, the defining caveat is that gastrointestinal intolerance drives most discontinuations and that a meaningful share of lost weight returns after stopping — this is chronic therapy, not a cure [15][14]. For retatrutide, it's the combination of unverified sourcing outside clinical trials and a dose-dependent heart-rate increase whose long-term cardiovascular meaning is still being studied in an ongoing outcomes trial [9]. For MOTS-c, the caution is the most fundamental of the three: there is no human efficacy or safety trial to point to at all, so any claim about what exogenous MOTS-c does in a person is, today, an extrapolation from mice and cells, not a demonstrated human effect.